The origin and global emergence of adamantane resistant A/H3N2 influenza viruses  by Nelson, Martha I. et al.
Virology 388 (2009) 270–278
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roThe origin and global emergence of adamantane resistant A/H3N2 inﬂuenza viruses
Martha I. Nelson a,⁎, Lone Simonsen b, Cécile Viboud a, Mark A. Miller a, Edward C. Holmes a,c
a Fogarty International Center, National Institutes of Health, Bethesda, MD 20892, USA
b Department of Global Health, School of Public Health and Health Services, The George Washington University, 2175 K Street NW, Washington, DC 20037, USA
c Center for Infectious Disease Dynamics, Department of Biology, The Pennsylvania State University, University Park, PA 16802, USA⁎ Corresponding author. Fax: +1 301 496 8496.
E-mail address: nelsonma@mail.nih.gov (M.I. Nelson
0042-6822/$ – see front matter © 2009 Elsevier Inc. A
doi:10.1016/j.virol.2009.03.026a b s t r a c ta r t i c l e i n f oArticle history:
Received 14 January 2009
Returned to author for revision
20 February 2009
Accepted 19 March 2009
Available online 24 April 2009
Keywords:
Human inﬂuenza A virus
Evolution
Adamantane resistance
Reassortment
Global migrationResistance to the adamantane class of antiviral drugs by human A/H3N2 inﬂuenza viruses currently
exceeds 90% in the United States and multiple Asian countries. Adamantane resistance is associated with a
single amino acid change (S31N) in the M2 protein, which was shown to rapidly disseminate globally in
2005 in association with a genome reassortment event. However, the exact origin of inﬂuenza A/H3N2
viruses carrying the S31N mutation has not been characterized, particularly in South-East Asia. We
therefore conducted a phylogenetic analysis of the HA, NA, and M1/2 segments of viral isolates collected
between 1997 and 2007 from temperate localities in the Northern hemisphere (New York State, United
States, 492 isolates) and Southern hemisphere (New Zealand and Australia, 629 isolates) and a subtropical
locality in South-East Asia (Hong Kong, 281 isolates). We ﬁnd that although the S31N mutation was
independently introduced at least 11 times, the vast majority of resistant viruses now circulating globally
descend from a single introduction that was ﬁrst detected in the summer of 2003 in Hong Kong. These
resistant viruses were continually detected in Hong Kong throughout 2003–2005, acquired a novel HA
through reassortment during the ﬁrst part of 2005, and thereafter spread globally. The emergence and
persistence of adamantane resistant viruses in Hong Kong further supports a source-sink model of global
inﬂuenza virus ecology, in which South-East Asia experiences continuous viral activity and repeatedly
seeds epidemics in temperate areas.© 2009 Elsevier Inc. All rights reserved.Introduction
After four decades of effective use of the adamantane class of
antiviral drugs in the prophylaxis and treatment of inﬂuenza,
global resistance to these drugs has increased dramatically among
inﬂuenza viruses of the A/H3N2 subtype in recent years. In the
vast majority of cases, the basis for resistance is a single Ser to Asn
amino acid replacement (S31N) in the matrix M2 ion channel,
which interferes with the drug's ability to block M2 ion channel
activity and viral replication (Wang et al., 1993; Aoki 1998).
Whereas b2% of A/H3N2 inﬂuenza viruses sampled globally were
resistant to adamantane during 1995–2002, resistance was detected
among 12.3% of viruses collected in 2004 (Bright et al., 2005).
Sharp increases in adamantane resistance ﬁrst appeared in Asia,
particularly in China, where the prevalence of resistance increased
from 8.2% in 2002 to 73.8% in 2004, and also in Hong Kong (69.8%
resistance in 2004) (Bright et al., 2005). Recently, the S31N
mutation was detected in 100% of inﬂuenza viruses sampled from
multiple Asian countries, although sample sizes were relatively).
ll rights reserved.small (Deyde et al., 2007). In the United States, adamantane
resistant inﬂuenza viruses emerged somewhat later, with preva-
lence increasing from b2% in 2003 to 11% in 2004–2005, and over
90% during the 2005–2006 epidemic (Bright et al., 2005; Bright et
al., 2006). Since 2006 the USA Centers for Disease Control and
Prevention (CDC) has recommended the cessation of use of
adamantanes for treatment or prophylaxis of inﬂuenza (CDC 2006).
Our understanding of the evolutionary basis for this dramatic
global increase in adamantane resistant inﬂuenza viruses remains
incomplete, particularly the role, if any, of direct selection for drug
resistance. Although mutations conferring drug resistance emerge
readily when adamantanes are administered to control inﬂuenza
outbreaks in nursing homes and long-term care facilities (Shiraishi
et al., 2003; Suzuki et al., 2003), resistant strains typically persist
only transiently. Accordingly, the prevalence of resistance to
adamantane at a population level has remained low for many
decades (b2%), despite periods of signiﬁcant adamantane usage in
certain areas, such as Japan in the late 1990s (Ziegler et al., 1999;
Masuda et al., 2000).
The rise of adamantane resistance in countries where the use of
adamantane drugs has not increased in recent years, such as in the
United States and Australia, implicates evolutionary mechanisms
other than local drug selection pressure (Simonsen et al., 2007;
271M.I. Nelson et al. / Virology 388 (2009) 270–278Barr et al., 2007a). In particular, it has been proposed that the
increased global frequency of the S31N mutation in the M2 protein
resulted from a chance hitchhiking event involving linkage to
advantageous mutations in other segments following a major 4+4
reassortment event, including mutations in HA1 at positions 193
and 225 near the receptor-binding site (Simonsen et al., 2007).
This reassortment event, which most likely occurred in early 2005,
generated a new global lineage of adamantane resistant A/H3N2
viruses, termed the ‘N-lineage’, characterized by an antigenically A/
Wisconsin/67/2005-like HA and an M2 protein bearing the S31N
replacement (Simonsen et al., 2007). Further characterization of
inﬂuenza viruses circulating globally identiﬁed additional indepen-
dent introductions of resistant A/H3N2 inﬂuenza viruses that
emerged prior to the emergence of the ‘N-lineage’, but which did
not spread globally (Deyde et al., 2007). However, the speciﬁc roles
of local evolution, migration, and reassortment in the genesis of
adamantane resistance in years prior to the global emergence of
the ‘N-lineage’ are unknown.
Although reassortment and genomic hitchhiking appear to be
important in the global dissemination of A/H3N2 adamantane
resistant viruses to North America and Oceania, it is possible that
localized direct selection pressure for drug resistance underlies the
initial emergence of adamantane resistance in South-East Asia. In
particular, the over-the-counter use of adamantane drugs may have
increased in some areas, including China, possibly in association with
the recent outbreaks of severe acute respiratory syndrome (SARS) and
H5N1 avian inﬂuenza virus (Bright et al., 2006; Deyde et al., 2007,
Hayden 2006). Furthermore, it has been proposed that South-East
Asia serves as an epicenter for continuous inﬂuenza virus activity,
with antigenic variants emerging in tropical South-East Asian
countries before disseminating globally (Russell et al., 2008). Accord-
ing to the ‘source-sink’ model of inﬂuenza A virus evolution, tropical
regions in general support continual viral activity, greater genetic
diversity, and consequently stronger natural selection, whereas
epidemics in temperate areas repeatedly die out due to strong
seasonal bottlenecks and require continual re-seeding (Rambaut et al.,
2008; Nelson et al., 2007, 2006; Tang et al. 2008a). Overall, the
seasonality of inﬂuenza in the tropics is less deﬁned than in temperate
regions but in some areas is associated with high rainfall (Shek and
Lee 2003).
The city of Hong Kong has a subtropical climate with a
semiannual pattern of inﬂuenza virus activity, with one peak in
winter and a second peak in late spring or early summer, although
in some years only one peak occurs (Wong et al., 2006; Yang et al.,
2008). Given the early detection of adamantane resistant viruses in
China and Hong Kong (Bright et al., 2005) and the prominence of
South-East Asia in global inﬂuenza virus evolution (Russell et al.,
2008), we sought to investigate the speciﬁc role of Hong Kong in
the origin and rapid global dissemination of adamantane resistant
viruses between 1997 and 2007. As drug selection pressure alone
inadequately explains the global domination of adamantane
resistant viruses in temperate countries where adamantane usage
has not increased in recent years, we explored how the interaction
between local evolution, genomic reassortment, and ongoing
antigenic change more completely explains the rapid global
dissemination of adamantane resistance. In particular, to under-
stand the global emergence of the S31N adamantane resistance
mutation within the context of antigenic evolution, we conducted a
phylogenetic analysis of inﬂuenza virus sequence data for the HA,
M1/2, and NA segments that was obtained through ten years of
sampling in both subtropical and temperate regions.
Results
Of the 1402 viral isolates sampled between 1997 and 2007 that
are included in this analysis, 119 (8.5%) exhibited the S31Nmutation in the M2 protein conferring resistance to adamantane
antiviral drugs. In Australia and New Zealand, 6.2% (39/629) of
isolates were resistant to adamantane drugs, 4.5% (22/492) of the
isolates from New York State, USA were adamantane resistant, and
20.6% (58/281) of Hong Kong isolates were resistant (Supplemen-
tary Tables 1–3). In the years prior to the global proliferation of
adamantane resistance viruses associated the emergence of the ‘N-
lineage’ in early 2005 (Simonsen et al., 2007), the overall
prevalence of adamantane resistance in our data set was 3.0%
(38/1250): 11.0% (27/246) in Hong Kong, 0.6% (3/533) in New
Zealand/Australia, and 1.7% (8/471) in New York State. Following
the emergence of the ‘N-lineage’ in 2005, the prevalence of
resistance increased to 53.3% (81/119): 88.6% (31/35) in Hong
Kong, 66.7% (14/21) in New York, and 37.5% (36/96) in Australia
and New Zealand. The prevalence of resistance is somewhat lower
in New Zealand due to the paucity of isolates from 2006 to 2007.
Phylogenetic analysis of the M1/2 segment of A/H3N2 inﬂuenza
virus isolates collected from Hong Kong, New York State, Australia,
and New Zealand reveals at least 11 independent introductions
(i.e., 11 separate clades) of the S31N mutation between the years
1997 and 2007 (Fig. 1, Table 1). This estimate is conservative, as
clusters of genetically related resistant isolates are regarded as a
single introduction of the S31N replacement even though it is
possible (although less parsimonious) that the mutation arose
independently among these isolates rather than through viral
transmission.
The ﬁrst introduction of S31N that is observed in these data
occurred in Hong Kong in 1997 (isolate A/Hong Kong/CUHK4245/
1997, Introduction #1, Fig. 1, Table 1). Notably, this isolate is
involved in a reassortment event, as A/Hong Kong/CUHK4245/
1997 is related to a clade of A/Wuhan/359/1995-like isolates in
the HA tree (shaded in blue, Fig. 2), but on the M1/2 and NA
phylogenies this isolate is closely related to A/Sydney/5/97-like
isolates (shaded in pink, Figs. 1 and 3). Such phylogenetic
incongruity suggests that a reassortment event involving the M1/
2 and NA occurred prior to the jump between the Wuhan/95 and
Sydney/97 antigenic clusters (Smith et al., 2004), such that A/
Wuhan/359/1995-like viruses ﬁrst acquired novel NA and M1/2
segments approximately 10–12 months before acquiring an anti-
genically divergent A/Sydney/5/1997-like HA.
That antigenically similar isolates (based on the HA phylogeny)
occupy divergent phylogenetic positions on the M1/2 and NA
phylogenies indicates that reassortment involving these three
segments has occurred on a regular basis over this decade of
sampling (Figs. 1–3). Whereas the evolution of the HA segment is
strongly linear and temporally structured (Fig. 2), reﬂecting the
action of continual selection for antigenic novelty, multiple clades
from the same time period occupy highly divergent phylogenetic
positions and the NA and M1/2 trees (Figs. 1 and 3), providing a
clear signature of reassortment. For example, at least four distinct
lineages of A/Sydney/5/1997-like isolates and four distinct lineages
of A/Fujian/411/2002-like isolates co-circulate on both the M1/2
and NA phylogenies, as indicated by the phylogenetically divergent
clusters of isolates shaded in pink and light green, respectively, on
the M1/2 and NA trees (Figs. 1 and 3). While the genetic diversity
of the HA appears to be restricted at a given time, inﬂuenza viruses
clearly periodically acquire novel M1/2 and NA segments through
reassortment.
Notably, isolate A/Hong Kong/CUHK4245/1997 is the only S31N
mutant from 1997 in our data set and is related to no other
adamantane resistant isolates, compatible with no or limited
spread of this virus in this viral population. The second emergence
of the S31N substitution involves a A/Sydney/5/1997-like isolate
from New York State (A/New York/512/1998, Introduction #2,
Table 1, Fig. 1). This introduction involves a single isolate, again
indicative of limited or no spread in this population at this level of
Fig. 1. Phylogenetic relationships of the M1/2 segment of 226 A/H3N2 inﬂuenza viruses sampled from Hong Kong (n=108), New York State, USA (n=72), and New Zealand and
Australia (n=46) between 1997 and 2007, estimated using an ML method. Isolates are shaded by antigenic characteristics (inferred from HA tree): A/Wuhan/359/1995-like
(WU95) isolates are blue, A/Sydney/5/1997-like (SY97) isolates are pink, A/Fujian/411/2002-like (FU02) isolates are green, A/California/07/2004-like (CA04) isolates are purple,
A/Wisconsin/67/2005-like (WI05) isolates are yellow, and A/Brisbane/10/2007-like (BR07) isolates are brown. In addition, isolates bearing the S31N mutation are shaded in red.
Independent introductions of the S31N replacement are numbered #1–#11. Bootstrap values (N70%) are shown for key nodes. The tree is rooted by the oldest isolate (A/New York/
564/1997, 01/02/1997), and all horizontal branch lengths are drawn to scale.
272 M.I. Nelson et al. / Virology 388 (2009) 270–278detection. It is also possible that this introduction represents an
instance of within-host evolution of adamantane resistance in
response to drug therapy, given that the patient from whom this
isolate was collected was 80 years old (Table 1) and the elderly
routinely receive adamantane drugs in the United States (Cohen et
al., 2008; Couch 2000).
Introduction #3 involves two A/Sydney/5/1997-like isolates, A/
New York/315/1999 and A/New York/324/1999, which were col-
lected on January 6, 1999 and January 26, 1999, respectively (Table 1,
Fig. 1). To be as conservative as possible in our estimate of
independent introductions of the S31N mutation, we regard these
two isolates as a single introduction, given the phylogenetic similarity
of these two isolates, their geographic and temporal proximity, and
the low number of S31Nmutations detected at this time. However, it is
possible that these S31N both arose de novo and represent
independent introductions, rather than being transmitted through a
network of New York State viruses not sampled in our study
population.
Introduction #4 involves another New York State isolate collected
in 1999 (A/New York/280/1999). However, as this introduction is
associated with a single virus, we again assume that it experienced
little or no spread in this population. In fact, no adamantane resistant
isolates are detected in any locality during 2000–2001, a period whenA/H1N1 inﬂuenza viruses were dominant (CDC 2001). In 2002 the
S31N mutation is ﬁrst detected in Oceania (Introduction #5),
involving the two A/Sydney/5/1997-like isolates A/Wellington/71/
2002 and A/Wellington/79/2002 (Fig. 1, Table 1). Again, given the
geographic and temporal proximity of these phylogenetically related
isolates, we infer that this occurrence of the S31N mutation has
disseminated locally in New Zealand (Table 1).
The ﬁrst S31N introduction that exhibits possible spread
between multiple localities is Introduction #6, which is detected
ﬁrst in Australia on 08/25/2003 (A/Queensland/34/2003) and
subsequently observed twice in New York State (A/New York/1/
2003, 10/28/2003; A/New York/31/2004, 01/05/2004) (Table 1).
Introduction #6 also represents the ﬁrst S31N mutation observed
among A/Fujian/411/2002-like viruses. Given the time and
distance separating these three isolates, it is possible that each
isolate represents a separate introduction of the S31N mutation,
although there is insufﬁcient phylogenetic resolution in this section
of the M1/2 phylogeny to distinguish between the single versus
multiple introductions of these three isolates (Fig. 1). Again, to be
conservative in the number of independent introductions, we
suggest that this introduction spread from the summer 2003
epidemic in Australia to the winter 2003–2004 epidemic in New
York State (Table 1).
Table 1
Isolate name, location and date of collection, patient age, and antigenic characterization of 71 adamantane resistant A/H3N2 inﬂuenza viruses that are associated with Introductions
#1–11 of the S31N mutation depicted in Fig. 1.
Introduction Isolate name Location Patient age Date of collection Antigenicity
#1 A/Hong Kong/CUHK4245/1997 HK 1–10 y 03/14/1997 A/Wuhan/1995-like
#2 A/New York/512/1998 NYS 80 y 01/29/1998 A/Sydney/5/1997-like
#3 A/New York/315/1999 NYS 31 y 01/06/1999 A/Sydney/5/1997-like
A/New York/324/1999 NYS 84 y 01/26/1999 A/Sydney/5/1997-like
#4 A/New York/280/1999 NYS 80 y 04/12/1999 A/Sydney/5/1997-like
#5 A/Wellington/71/2002 AUS/NZ 62 y 07/15/2002 A/Sydney/5/1997-like
A/Wellington/79/2002 AUS/NZ 11 y 08/20/2002 A/Sydney/5/1997-like
#6 A/Queensland/34/2003 AUS/NZ 11 mo 08/25/2003 A/Fujian/411/2002-like
A/New York/1/2003 NYS 21 y 10/28/2003 A/Fujian/411/2002-like
A/New York/31/2004 NYS 66 y 01/05/2004 A/Fujian/411/2002-like
#7 A/Hong Kong/CUHK50895/2003 HK 1–10 y 07/06/2003 A/Fujian/411/2002-like
A/Hong Kong/CUHK51353/2003 HK 1–10 y 07/18/2003 A/Fujian/411/2002-like
A/Hong Kong/CUHK52011/2003 HK 1–10 y 08/05/2003 A/Fujian/411/2002-like
A/New York/204/2003 NYS 39 y 08/16/2003 A/Fujian/411/2002-like
A/Hong Kong/CUHK52467/2003 HK 1–10 y 08/18/2003 A/Fujian/411/2002-like
A/Hong Kong/CUHK52923/2003 HK 1–10 y 08/26/2003 A/Fujian/411/2002-like
A/Hong Kong/CUHK71313/2003 HK 1–10 y 09/21/2003 A/Fujian/411/2002-like
A/Hong Kong/CUHK24289/2004 HK 1–10 y 04/02/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK33677/2004 HK 1–10 y 05/04/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK33851/2004 HK 1–10 y 05/08/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK35013/2004 HK 1–10 y 06/01/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK50600/2004 HK 1–10 y 07/06/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK50563/2004 HK 1–10 y 07/06/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK52274/2004 HK 1–10 y 08/06/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK52677/2004 HK 1–10 y 08/13/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK52863/2004 HK 1–10 y 08/17/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK52941/2004 HK 1–10 y 08/18/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK53726/2004 HK 1–10 y 09/02/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK53766/2004 HK 1–10 y 09/03/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK53732/2004 HK 1–10 y 09/03/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK6422/2005 HK 1–10 y 01/31/2005 A/Fujian/411/2002-like
A/Hong Kong/CUHK6898/2005 HK 1–10 y 02/12/2005 A/Fujian/411/2002-like
A/Hong Kong/CUHK7221/2005 HK 1–10 y 02/20/2005 A/Fujian/411/2002-like
A/Hong Kong/CUHK7546/2005 HK 1–10 y 02/27/2005 A/Fujian/411/2002-like
A/Hong Kong/CUHK7711/2005 HK 1–10 y 03/01/2005 A/Wisconsin/67/05-like
A/Hong Kong/CUHK7733/2005 HK 1–10 y 03/02/2005 A/Fujian/411/2002-like
A/Hong Kong/CUHK11949/2005 HK 1–10 y 04/28/2005 A/Wisconsin/67/05-like
A/Canterbury/24/2005 AUS/NZ 54 y 05/04/2005 A/Wisconsin/67/05-like
A/Otago/1/2005 AUS/NZ 28 y 07/01/2005 A/Wisconsin/67/05-like
A/Hong Kong/CUHK42241/2005 HK 1–10 y 07/02/2005 A/Wisconsin/67/05-like
A/Hong Kong/CUHK42644/2005 HK 1–10 y 07/09/2005 A/Wisconsin/67/05-like
A/Queensland/51/2005 AUS/NZ 12 y 07/12/2005 A/Wisconsin/67/05-like
A/Hong Kong/CUHK43751/2005 HK 1–10 y 07/26/2005 A/Wisconsin/67/05-like
A/Canterbury/234/2005 AUS/NZ 42 y 07/27/2005 A/Wisconsin/67/05-like
A/Western Australia/29/2005 AUS/NZ 1 y 08/03/2005 A/Wisconsin/67/05-like
A/New York/923/2006 NYS 13 y 02/23/2006 A/Wisconsin/67/05-like
A/New York/933/2006 NYS 17 y 03/01/2006 A/Wisconsin/67/05-like
A/Hong Kong/CUHK53004/2006 HK 1–10 y 03/04/2006 A/Wisconsin/67/05-like
A/Hong Kong/CUHK53005/2006 HK 1–10 y 03/04/2006 A/Wisconsin/67/05-like
A/Hong Kong/CUHK53798/2006 HK 1–10 y 03/17/2006 A/Wisconsin/67/05-like
A/Hong Kong/CUHK53907/2006 HK 1–10 y 03/19/2006 A/Wisconsin/67/05-like
A/New York/6/2006 NYS 15 y 04/06/2006 A/Wisconsin/67/05-like
A/Hong Kong/CUHK60052/2006 HK 1–10 y 06/29/2006 A/Wisconsin/67/05-like
A/Hong Kong/CUHK64082/2006 HK 1–10 y 09/10/2006 A/Wisconsin/67/05-like
A/Hong Kong/CUHK65241/2006 HK 1–10 y 09/28/2006 A/Wisconsin/67/05-like
A/Hong Kong/CUHK66001/2006 HK 1–10 y 10/13/2006 A/Wisconsin/67/05-like
A/Hong Kong/CUHK45130/2006 HK 1–10 y 12/04/2006 A/Wisconsin/67/05-like
A/Hong Kong/CUHK69904/2006 HK 1–10 y 12/29/2006 A/Wisconsin/67/05-like
A/New York/UR06-0040/2007 NYS 45 y 01/17/2007 A/Brisbane/10/07-like
A/New York/UR06-0437/2007 NYS 24 y 02/27/2007 A/Brisbane/10/07-like
A/New York/UR06-0510/2007 NYS 10 y 03/05/2007 A/Wisconsin/67/05-like
A/New York/UR06-0529/2007 NYS 34 y 03/06/2007 A/Brisbane/10/07-like
A/New York/UR06-0607/2007 NYS 8 y 03/14/2007 A/Brisbane/10/07-like
#8 A/Hong Kong/CUHK13126/2004 HK 1–10 y 02/02/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK21164/2004 HK 1–10 y 02/12/2004 A/Fujian/411/2002-like
A/Hong Kong/CUHK24289/2004 HK 1–10 y 04/02/2004 A/Fujian/411/2002-like
#9 A/Hong Kong/CUHK35011/2004 HK 1–10 y 06/01/2004 A/Fujian/411/2002-like
#10 A/New York/391/2005 NYS 37 y 01/07/2005 A/California/7/04-like
#11 A/Wellington/9/2005 AUS/NZ 29 y 08/23/2005 A/California/7/04-like
A/Otago/3/2005 AUS/NZ 19 y 08/31/2005 A/California/7/04-like
A/Otago/4/2005 AUS/NZ 19 y 08/31/2005 A/California/7/04-like
Viruses are sorted by isolation dates.
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Fig. 2. Phylogenetic relationships of the HA gene segment of 231 A/H3N2 inﬂuenza viruses sampled from Hong Kong (n=108), New York State, USA (n=72), New Zealand and
Australia (n=46) between 1997 and 2007, and 5 inﬂuenza vaccine reference strains (A/Sydney/5/1997, A/Wyoming/3/2003 (A/Fujian/411/2002-like), A/California/7/2004, A/
Wisconsin/67/2005, and A/Brisbane/10/2007), estimated using an ML method. Labels, shading, and rooting are the same as for Fig. 1, with Introductions #1–#11 referring to those
identiﬁed in Fig. 1 and inﬂuenza vaccine reference strains shaded in dark green. Isolates labeled ‘#7F’ are associated with Introduction #7 and are A/Fujian/411/2002-like, and
isolates labeled ‘7W’ are associated with Introduction #7 and are A/Wisconsin/67/2005-like.
274 M.I. Nelson et al. / Virology 388 (2009) 270–278Notably, A/Queensland/34/2003, A/New York/1/2003, and A/
New York/31/2004 are members of a clade of A/Fujian/411/2002-
like isolates that was involved in a major reassortment event
associated with the jump from Sydney/97 to Fujian/02 antigenic
clusters (Holmes et al., 2005). Although these isolates cluster with
A/Fujian/411/2002-like isolates on the HA tree (Fig. 2), they are
members of a clade that is related to older A/Sydney/5/1997-like
isolates on both the M1/2 and NA trees (Figs. 1 and 3). The ﬁrst A/
Fujian/411/2002-like isolates observed in our data set are non-
reassortant and detected during the summer of 2002 in Hong Kong
(A/Hong Kong/CUHK33199/2002, 07/04/2002; A/Hong Kong/
CUHK34193/2002, 08/02/2002). Non-reassortant A/Fujian/411/
2002-like isolates also are detected in New York State in the
winter of 2002–2003 (e.g., A/New York/485/2003, 01/06/2003).
However, all A/Fujian/411/2002-like isolates from Oceania that
emerge in the summer of 2003 are reassortant, with NA and M1/2
segments that derive from the major clade of A/Sydney/5/1997-
like isolates. Reassortant A/Fujian/411/2002-like isolates are sub-
sequently detected in New York State and Hong Kong during the
2003–2004 season. These reassortant M1/2 and NA lineages
continue to circulate for at least a year (last detected in October
2004 in Australia) before dying off during a purging of genetic
diversity associated with the selective sweep of the A/California/7/
2004-like viruses (Rambaut et al., 2008).Whereas the six previous introductions of the S31N mutation
likely exhibit limited spread in time and space, Introduction #7 is
continually detected among this viral population for more than
3.5 years (from 07/06/2003 to 03/14/2007) and gives rise to the
majority of adamantane resistant isolates in our data set, including the
major ‘N-lineage’ that is associated with the global spread of
adamantane resistance that begins in 2005 (Table 1, Fig. 1) (Simonsen
et al., 2007). Introduction #7 is ﬁrst detected in Hong Kong on 07/06/
2003 (A/Hong Kong/CUHK50895/2003) and is continually detected
in Hong Kong for nearly two years (through 04/28/2005) (Table 1). A
single resistant isolate is observed during this time outside of Hong
Kong (A/New York/204/2003, 08/16/2003), but during the non-
epidemic summer months in New York State and is likely to be a spill-
over from Asia (Table 1, Fig. 1).
All resistant isolates circulating in Hong Kong from 2003 to 2004
are A/Fujian/411/2002-like in antigenicity. However, in the early
spring of 2005 these resistant viruses acquire an antigenically novel
HA segment described as A/Wisconsin/67/2005-like, at which point
this lineage has been referred to as the ‘N-lineage’ (Simonsen et al.,
2007). This reassortment event is evidenced by the phylogenetic
distance on the HA tree between two sets of isolates that are both
closely related on the M1/2 tree in association with Introduction #7
(Figs. 2 and 1, respectively). On the HA tree, one of these sets clearly is
A/Fujian/411/2002-like (‘#7F’, Fig. 2), while the other is A/
Fig. 3. Phylogenetic relationships of the NA gene segment of 226 A/H3N2 inﬂuenza viruses sampled from Hong Kong (n=108), New York State, USA (n=72), and New Zealand and
Australia (n=46) between 1997 and 2007, estimated using anMLmethod. Labels, shading, and rooting are the same as for Figs. 1 and 2, with Introductions #1–#11 referring to those
identiﬁed in Fig. 1.
275M.I. Nelson et al. / Virology 388 (2009) 270–278Wisconsin/67/2005-like (‘#7W’, Fig. 2). In addition, the four
phylogenetically distinct clusters of ‘#7F’ isolates on the HA tree
suggest that A/Fujian/411/2002-like isolates may have acquired the
#7 S31N introduction through multiple additional reassortment
events. The phylogenetic divergence between two clusters of ‘#7F’
isolates is particularly pronounced on the NA tree (‘#7F1’ and ‘#7F2’,
Fig. 3), providing clear evidence of reassortment in this case.
The ﬁrst of the reassortant ‘N-lineage’ isolates is detected in
Hong Kong on March 1, 2005 (A/Hong Kong/CUHK7711/2005)
(Table 1). Adamantane resistant reassortant isolates rapidly pro-
liferate globally thereafter, emerging in Oceania by the late spring of
2005 and reaching New York State during the 2005–2006 winter
epidemic (Table 1). An expanded phylogenetic analysis of the M1/2
segment that includes additional adamantane resistant isolates
collected globally from 1997 to 2007, mainly from South-East Asia
from 2003 to 2005, indicates that the ‘N-lineage’ circulated widely
in South-East Asia during the late spring and summer of 2005,
including Vietnam, Malaysia, Philippines, Thailand, and Macau
(Supplementary Fig. 1). Notably, none of the additional global
isolates in the ‘N-lineage’ isolates was sampled prior to the original
03/01/2005 emergence date we identiﬁed in Hong Kong. Nor do
any of the global background isolates associated with Introduction
#7 pre-date its ﬁrst detection in Hong Kong on 07/06/2003
(Supplementary Fig. 1). As expected, the majority of these globalresistant isolates are associated with the main Introduction #7, and
all 2005 global isolates are members of the ‘N-lineage.’
The third independent introduction of the S31N mutation
among A/Fujian/411/2002-like viruses is detected in 2004 invol-
ving three isolates from Hong Kong (Introduction #8, Table 1, Fig.
1), while the fourth, Introduction #9, occurs along a phylogeneti-
cally divergent lineage of the M1/2 segment that is primarily
sensitive to adamantane drugs (isolate A/Hong Kong/CUHK35011/
2004) (Table 1, Fig. 1). Despite the global dominance of
adamantane resistant inﬂuenza viruses from 2005 to 2007, a
phylogenetically distinct lineage of the M1/2 segment that for the
most part lacks the S31N substitution co-circulates from 2004 to
2007 (Fig. 1). This adamantane sensitive lineage includes all of the
A/California/7/2004-like isolates, as well as small clusters of
sensitive A/Fujian/411/2002-like and A/Wisconsin/67/2005-like
isolates. Consequently, while the vast majority of A/Wisconsin/
67/2005-like isolates are resistant to adamantanes, several A/
Wisconsin/67/2005-like isolates are adamantane sensitive due to
reassortment with this sensitive M1/2 lineage that co-circulates:
isolates A/Canterbury/127/2005, A/Hong Kong/CUHK63957/2006,
A/Hong Kong/CUHK68792/2006, A/New York/UR06-373/2007,
and A/New York/UR06-515/2007 (Figs. 1 and 2).
Two additional introductions of the S31N mutation occur
among this adamantane sensitive M1/2 lineage, both involving
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single isolate, A/New York/391/2005 (Table 1, Fig. 1), and
Introduction #11 consists of a cluster of three isolates detected
during the summer of 2005 in New Zealand: A/Otago/3/2005, A/
Otago/4/2005, and A/Wellington/9/2005 (Table 1, Fig. 1). These
three isolates are separated by only 8 days and relatively little
geographic distance, suggesting limited local spread. Following this
last introduction of the S31N mutation in the summer of 2005, all
adamantane resistant inﬂuenza viruses hereon are associated with
the ‘N-lineage’, strongly suggesting that this clade has a major
ﬁtness advantage.
Discussion
Whereas previous phylogenetic analyses of the emergence and
evolution of adamantane resistant inﬂuenza viruses have been limited
by the lack of data from subtropical regions, or by a primary focus on
the evolution of the HA1 region (Simonsen et. al. 2007; Deyde et al.,
2007), this study is the ﬁrst to incorporate multi-segment sequence
data intensively sampled from a subtropical locality in South-East
Asia. By tracing the evolution of adamantane resistance among three
geographically and climatically distinct localities for the HA, M1/2,
and NA segments, we are able to determine evolutionary processes
operating at both regional and global scales. Given that the
therapeutic usage of adamantane drugs has been at a constant and
relatively low level for many decades in temperate areas, including the
United States, simple models based on local drug selection pressures
alone inadequately explain the rapid rise in the global prevalence of
adamantane resistance in recent years. Rather, we ﬁnd that the
emergence and spread of adamantane resistance appears to be a
complex evolutionary process that includes geographically variable
selection pressures, extensive global migration, and frequent
reassortment.
Speciﬁcally, our ﬁndings indicate that adamantane resistance
independently emerged at least 11 times throughout 1997–2007 in
all three globally dispersed localities. This estimate is also conserva-
tive, given the limitations of our sampling and our capacity to identify
additional de novo introductions among genetically related resistant
isolates. As several introductions of the resistant S31N mutation were
detected in elderly patients in temperate regions where adamantane
is more frequently administered to seniors (Cohen et al., 2008; Couch
2000), it is possible that intra-host selectionwas involved in a number
of these introductions. However, 10/11 of these introductions were
represented by no more than three isolates in each case, suggesting
that these introductions experienced only limited in spread in our
studied population, and that drug selection pressure alone was
insufﬁcient to increase the prevalence of S31N.
Importantly, the vast majority of adamantane resistant inﬂuenza
virus isolates in our data set descend from a single introduction
(Introduction #7), which is ﬁrst detected in July 2003 in Hong
Kong, where it was detected continually for almost two years (and
likely was present in other South-East Asian locations sparsely
sampled in this study), before spreading globally following the
major reassortment event in March 2005 and the emergence of the
‘N-lineage’ (Simonsen et al., 2007). Given the lack of viral sequence
data from other South-East Asian countries, it is not possible to
determine whether the viral lineage associated with Introduction
#7 persisted in Hong Kong or was continually re-introduced into
Hong Kong from neighboring South-East Asian countries over this
time period, such as other parts of China.
Although Introduction #7 is present in Hong Kong for several
years, it is only through reassortment with a novel HA (A/
Wisconsin/67/2005-like) that this resistant M1/2 lineage is able to
spread globally. Although our data set is limited to the HA, NA, and
M1/2 segments, we were still able to observe a number of
reassortment events among these three genome segments. Whilegenetic diversity appears to be more limited in the HA, presumably
due to strong immune selection pressures, multiple divergent
lineages co-circulated on the NA and M1/2 phylogenies prior to the
selective sweep associated with the emergence of A/California/7/
2004-like viruses that has been described previously (Rambaut et
al., 2008). It is this long-term preservation of genetic diversity in
the M1/2 segment that allows for the continued circulation of both
adamantane sensitive and adamantane resistant inﬂuenza viruses
to the present day. Indeed, just as inﬂuenza viruses acquired
adamantane resistance through reassortment in 2005, it has been
observed that resistant inﬂuenza viruses may re-acquire drug
sensitivity through reassortment with adamantane sensitive
lineages that continue to co-circulate in both the United States
(Nelson et al., 2008) and in Japan (Furuse et al., 2008).
Recent studies also suggest that South-East Asia may serve as a
reservoir for inﬂuenza A virus, continually re-seeding new
epidemics in temperate areas (Russell et al., 2008). Our ﬁndings
provide further evidence that South-East Asia serves as an
epicenter for inﬂuenza virus activity, with viral lineages such as
Introduction #7 originating in South-East Asia before disseminating
globally to temperate areas. Although our inclusion of background
global sequences from South-East Asia in our expanded phyloge-
netic tree (Supplementary Fig. 1) suggests that Hong Kong is likely
to be representative of the South-East Asian region for the
purposes of this study, intensive sampling from additional localities
in South-East Asia is greatly needed to understand the evolutionary
dynamics in this critical region. Further sampling would likely be
most proﬁtable in countries such as China, where high levels of
adamantane resistance were ﬁrst detected, and yet publicly
available inﬂuenza virus sequences are limited (Bright et al.,
2005, 2006).
Finally, the processes of local evolution, reassortment, and global
spread through genomic hitchhiking we observe in the spread of S31N
among A/H3N2 viruses are also likely to be involved in the recent
global proliferation of A/H1N1 inﬂuenza viruses that are resistant to
adamantanes (Deyde et al., 2007; Barr et al., 2007b), as well as in the
unexpected proliferation of the H274Y substitution conferring
resistance to NA inhibitors (oseltamivir) (Sheu et al., 2008; Besselaar
et al., 2008; Lackenby et al., 2008). Understanding the evolutionary
basis for the current proliferation of drug resistant viruses will be
particularly important for developing effective strategies for admin-
istering antiviral drugs in the event of a pandemic (Lackenby et al.,
2008), but will require the public availability of additional whole-
genome sequences from isolates collected intensively from multiple
global localities from the earliest time of resistance detection.
Methods
Phylogenetic analysis of inﬂuenza A viruses from Hong Kong, New York
State, USA, Australia and New Zealand from 1997 to 2007
All inﬂuenza A/H3N2 virus sequence data were collected from the
National Institute of Allergy and Infectious Disease's Inﬂuenza
Genome Sequencing Project (http://www.niaid.nih.gov/dmid/gen-
omes/mscs/inﬂuenza.htm) for the period 1997–2007. A total of 485
inﬂuenza A/H3N2 viruses from 1997 to 2006 were sampled from all
11 regions in New York State, USA, and were collected by the Virus
Reference and Surveillance Laboratory at the Wadsworth Center, New
York State Department of Health. In addition, we included 7 A/H3N2
inﬂuenza viruses that were collected in 2007 by Surveillance Data Inc.,
as part of a larger 2006–2007 U.S. surveillance effort. In Oceania, a
total of 629 inﬂuenza A/H3N2 viruses were sampled from both the
North and South Islands of New Zealand and from four territories in
Australia (Western Australia, New South Wales, South Australia, and
Queensland). Inﬂuenza viruses from New Zealand were collected by
Canterbury Health Laboratories in Christchurch, New Zealand. In
277M.I. Nelson et al. / Virology 388 (2009) 270–278Australia, viruses from New South Wales were collected by the Prince
of Wales Hospital, New South Wales; viruses from South Australia
were collected by the Institute of Medical and Veterinary Sciences,
South Australia; viruses from Queensland were collected by the
Queensland Health Science Services, Queensland; and viruses from
Western Australia were collected by PathWest Laboratory Medicine,
Western Australia. A total of 281 inﬂuenza A/H3N2 viruses from 1997
to 2006 (∼30 isolates from each year) were collected from children of
ages 1–10 presenting with acute respiratory illness to the Prince of
Wales Hospital in Hong Kong. In this case only the HA, NA, and M1/2
genome segments were available. Procedures for the isolation and
sequencing of these isolates have been described previously (Ghedin
et al., 2005; Tang et al., 2008a, 2008b). Accordingly, sequence data for
the coding regions of the HA, NA, and M1/2 for 281 inﬂuenza isolates
fromHong Kong (Supplementary Table 1), 492 inﬂuenza isolates from
New York State, USA (Supplementary Table 2), and 629 inﬂuenza
isolates from Australia and New Zealand (Supplementary Table 3)
were downloaded from the National Center for Biotechnology
Information (NCBI) Inﬂuenza Virus Resource (http://www.ncbi.nlm.
nih.gov/genomes/FLU/FLU.html) available on GenBank (Bao et al.,
2008). Dates of sampling were available on GenBank, and information
on patient age was available on GenBank for each inﬂuenza isolate
collected fromNewYork State, Australia, and NewZealand (but not for
Hong Kong) (Supplementary Tables 1–3).
Phylogenetic analysis
Sequence alignments were manually constructed for the major
coding regions for the HA, (1698 nt), NA (1407 nt), andM1/2 (979 nt)
using the Se-Al program (Rambaut 2002). To determine the evolu-
tionary relationships between all 1410 inﬂuenza isolates an initial
phylogenetic tree was inferred using neighbor-joining methods
available in PAUP⁎ (Swofford 2003), with the robustness of each
node determined through a bootstrap resampling process (1000
replications). Clades of related isolates were identiﬁed by high
bootstrap values (N70%) and exceptionally long branch lengths. The
occurrence of resistance to adamantane antiviral drugs was identiﬁed
through a visual screening for the S31N amino acid replacement in the
M2 protein using the Se-Al program (Rambaut 2002).
Due to the large number of closely related isolates that adds little
to a phylogenetic analysis of circulating lineages, we selected from the
original data set a representative data set of 226 inﬂuenza isolates
sampled from Hong Kong (n=108), New York State (n=72), and
Australia and New Zealand (n=46) (Supplementary Table 4). All
isolates that are resistant to adamantane drugs that emerged prior to
the emergence of the ‘N-lineage’were retained in this smaller data set,
as were all isolates that occupied divergent topological positions
across the HA, NA and M1/2 phylogenies, the earliest isolate that was
detected in each location (Hong Kong, New York State, and Australia/
New Zealand), and a maximum of four isolates for each season, each
location, and each antigenic type. We also included the following ﬁve
vaccine reference strains in our HA data set (n=231) to determine
antigenic groups: A/Sydney/5/1997, A/Wyoming/03/2003 (A/
Fujian/411/2002-like), A/California/07/2004, A/Wisconsin/67/
2005, and A/Brisbane/10/2007. To study the emergence of adaman-
tane resistance in a broader global context, an additional 20 A/H3N2
inﬂuenza virus isolates exhibiting the S31N adamantane resistance
mutation (and for which HA1 sequences were also available) were
identiﬁed, and M1/2 and HA1 sequence data was downloaded from
GenBank (Bao et al., 2008) and added to the original data sets
(n=246). These background isolates were collected between 2003
and 2005, mainly from South-East Asia (Macau, Malaysia, Philippines,
Singapore, Taiwan, Thailand, and Vietnam) (Supplementary Table 5).
The evolutionary relationships for the HA, M1/2, and NA among
these 226 inﬂuenza isolates (231 isolates for HA, including 5 vaccine
reference strains) were inferred using the maximum likelihood (ML)methods available in PAUP⁎ (Swofford 2003). In each case, the best-ﬁt
model of nucleotide substitution was identiﬁed by MODELTEST
(Posada and Crandall, 1998) as the general reversible (GTR+I+Γ4)
model, with the frequency of each substitution type, proportion of
invariant sites (I), and the gamma distribution of among-site rate
variation with four rate categories (Γ4) estimated from the empirical
data (parameter values available upon request). In all cases tree
bisection-reconnection (TBR) branch-swapping was utilized to deter-
mine the globally optimal tree. To assess the robustness of each node
on the phylogenetic tree, a bootstrap resampling process (1000
replications) using the neighbor-joining (NJ) method was used,
incorporating the ML substitution model. Clades of related isolates
were again identiﬁed by high bootstrap values (N70) and exception-
ally long branch lengths. Independent introductions of the S31N
replacement were inferred from clade positions on the M1/2
phylogeny and the location and dates of sampling.
The antigenic characterization of each isolate was inferred from its
phylogenetic position on the HA treewith respect to the ﬁve inﬂuenza
vaccine strains of known antigenicity: A/Sydney/5/1997, A/Wyom-
ing/3/2003, A/California/7/2004, A/Wisconsin/67/2005, and A/
Brisbane/10/2007. Speciﬁc amino acid changes along key branches
separating antigenic groups were identiﬁed using the MacClade
program (Maddison and Maddison 2000) (Supplementary Table 6).
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